Drug Profile
mRNA 1851
Alternative Names: H7 mRNA vaccine - Moderna Therapeutics; VAL 339851Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Developer Valera LLC
- Class Influenza A virus H7N9 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention) in USA (IM, Injection)
- 31 Dec 2020 Moderna Therapeutics has patent protection for mRNA 1851 in USA, prior to December 2020
- 23 Apr 2020 mRNA 1851 is still in phase-I development for Influenza A virus H7N9 subtype infections (Moderna Therapeutics pipeline, April 2020)